Defender Capital’s Lineage Cell Therapeutics LCTX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$8.64M Sell
6,598,899
-130,700
-2% -$181K 2.81% 12
2026
Q1
$10.6M Sell
6,729,599
-99,500
-1% -$168K 3.77% 11
2025
Q4
$11.4M Buy
+6,829,099
New +$11.8M 3.7% 10
2025
Q3
Sell
-6,785,177
Closed -$6.16M 19
2025
Q2
$6.16M Buy
6,785,177
+474,304
+8% +$281K 2.09% 12
2025
Q1
$3.16M Buy
6,310,873
+347,525
+6% +$204K 1.24% 12
2024
Q4
$3M Buy
5,963,348
+961,150
+19% +$706K 1.1% 12
2024
Q3
$4.53M Buy
5,002,198
+29,223
+0.6% +$27.1K 1.5% 12
2024
Q2
$4.96M Buy
4,972,975
+5,300
+0.1% +$5.85K 1.69% 12
2024
Q1
$7.35M Sell
4,967,675
-2,000
-0% -$2.27K 2.5% 12
2023
Q4
$5.42M Sell
4,969,675
-214,835
-4% -$235K 1.9% 12
2023
Q3
$6.12M Buy
5,184,510
+74,800
+1% +$102K 2.22% 10
2023
Q2
$7.2M Sell
5,109,710
-26,375
-0.5% -$36.4K 2.48% 10
2023
Q1
$7.7M Buy
5,136,085
+42,550
+0.8% +$59.4K 2.69% 10
2022
Q4
$5.96M Sell
5,093,535
-90,500
-2% -$114K 2.41% 10
2022
Q3
$5.86M Buy
5,184,035
+52,100
+1% +$76.5K 2.3% 10
2022
Q2
$8.11M Buy
5,131,935
+125,750
+3% +$166K 3.18% 10
2022
Q1
$7.98M Buy
5,006,185
+8,315
+0.2% +$12.9K 2.78% 11
2021
Q4
$12.2M Buy
4,997,870
+199,600
+4% +$467K 3.93% 9
2021
Q3
$12.7M Sell
4,798,270
-238,450
-5% -$612K 4.13% 9
2021
Q2
$14.4M Buy
5,036,720
+86,000
+2% +$223K 4.77% 9
2021
Q1
$11.6M Buy
4,950,720
+214,730
+5% +$516K 4.14% 9
2020
Q4
$8.34M Sell
4,735,990
-313,000
-6% -$438K 3.63% 8
2020
Q3
$4.73M Buy
5,048,990
+402,700
+9% +$356K 2.33% 10
2020
Q2
$4.04M Buy
4,646,290
+229,700
+5% +$202K 2.38% 9
2020
Q1
$3.66M Buy
4,416,590
+439,545
+11% +$438K 2.67% 10
2019
Q4
$3.54M Buy
3,977,045
+183,000
+5% +$152K 3.14% 8
2019
Q3
$3.71M Sell
3,794,045
-325,755
-8% -$337K 3.29% 7
2019
Q2
$4.27M Sell
4,119,800
-94,760
-2% -$109K 3.45% 7
2019
Q1
$5.57M Buy
4,214,560
+230,090
+6% +$286K 4.46% 6
2018
Q4
$3.63M Buy
+3,984,470
New +$6.1M 3.46% 6

Other funds holding LCTX